Serological and Hematological Study of Toxoplasmosis in Blood of Newly Born Babies
DOI:
https://doi.org/10.46966/msjar.v2i3.29Keywords:
Toxoplasmosis, Neonatal Infection, Toxoplasma GondiiAbstract
Serological identification and blood pictures were done for specific IgM and IgG.10% of cases were positive IgM of Toxoplasmosis because have 10 IU/ml (mean) in comparison with control group were 0.11 IU/ml (mean). On other hand 20% of diagnosed cases were positive IgG of Toxoplasmosis because have 11 IU/ml .Two cases were followed for their history one from group IgM and other IgG , first one suffered from three abortion and now have five child three of them healthy while two have congenital defects. Second case (IgG positive ) have four abortion and now have three child , two healthy and one have congenital defect. Blood picture reveal 40% suffered from Normocytic anemia , these cases classified to three groups , first Toxoplasma group 30% (positive in ELISA test). Second group (Unknown causes), these cases not only normocytic anemia also have high total leukocytes 17 x10 (mean) and high MCV (103 ft). Third group have low MCV 78ft.
References
Dubey, J.P. (1995). Toxoplasma gondii. Medical microbiology Chapter 84:pp:350.
Figueiro-Filho, E., Lopes, A., Senefonte, F., Souza,Junior, V.& Botelho, C. (2005). Toxoplasma gondii: Study the Frequency of vertical transmission diagnosis of Materno-fetalis. Rev.Bras. Ginecol. Obestet.27:442-9.
Foulon, W.(1992).Congenital Toxoplasmosis: is screening Desirable? Scand. J. Infect. Dis. 84(Suppl):11-7.
Gavinet, M.F. Robert,F. Firtion, G. et al.(1997).congenital Toxoplasmosis due to maternal reinfection during pregnancy. J. Clin. Microbiol. 35: 1276-7.
Guerina, N.et al (1994). Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The new England regional Toxoplasmoșis working group.N. Engl. J.Med. 330:1858-1863
Gilbert, R. and Gras, L.(2003).Effect of timing and type of treatment on the risk of mother to child transmission of T. gondi
European multicenter study on congenital Toxoplasmosis, V.(110). PP:112-120. Jenum, P. Stray-Pedersen, B.Melby, K. Kapperud, G. Whitelaw, A. Eskid, A. Eng.J.(1998). Incidence of T.gondii infection in 35,940 pregnant women in Norway and pregnancy outcome for infected women. J. Clin. Microbiol. 36:(10),2900-6.
Jones, J.L. Lopez, A. Wilson, M. Schulkin, J. Gibbs, R.(2001). Congenital Toxoplasmosis: A review.Obstet. Surv.56:296-305.
Jones, J.L. Lopez, A. | Wilson, M. (2003).Congenital Toxoplasmosis. Am.Fam. Physican . 67: 2131-8.
Matrin, F.(2000). Congenital Toxoplasmosis: Value of antenatal screening current prenatal treatment. Rev. Obste. Gynecol.1:46-51.
Marua, J.(2013). Bloody serological study of toxoplasmosis in pregnant women and newlyborn babies in Diwanyia, MSc thesis / Alqadisyia University.
Moura, F.L. Amendoeira, M.R. Bastos, O.M. Mattos, D.P. Fonseca, A.B. Nicolau, J. L.(2013). Prevalence and Risk factors for T.gondii infection among pregnant and postpartum women attended at public health care facilities in the city of Niteroi state of Rio de Janeiro, Brazil, Rev. Soc. Bras. Med. Trop.46:200-7.
Nimri, L. Pelloux, H. and Elkhatib, H. (2004). Detection of T. gondii and specific antibodies in high-risk pregnant women. Am. J. Trop. Med. Hyg. 71 (6):831-5.
Paquet, C. Yudin, M.(2013). Toxoplasmosis in pregnancy: Prevention screening and treatment. J. Obest. Gyna, Can. 35: 78-9. 15-
Remington, J. Mcleod, R. Wilson, C. Desmonts, G.(2010). Infectious diseases of the fetus and newborn infant. Text book, 17th thed. Pennsylvania: Elsevier. pp:918-1041.
Robbins, S. Cotran,R. Kumar, V. (2008). Pathologic Bases of disease. 9th ed. Saunders com., p.373.
Schmidt, S. Mazzelia, M. Nixon, R. Mathews, P. (2013). Ab measurement by ELISA methods in Molecular Biology , 849: 507-27.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 the Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
